OncoMark

OncoMasTR is a multi-parameter prognostic test for early-stage breast cancer that can rapidly, accurately and reliably stratify patients into low or high risk of cancer recurrence. This aids clinicians confidentially determine the best treatment options, thus avoiding overtreatment with unnecessary and aggressive chemotherapies. The test is based on patented technology that arose from a collaboration between Prof. Adrian Bracken at Trinity College Dublin (TCD) and Prof. William Gallagher at University College Dublin (UCD) in 2012 and was then exclusively licensed to OncoMark, a UCD spin-out, in 2014. OncoMark subsequently developed and validated the test which led to an acquisition of the company by a large US firm and a new start-up company.